Trials

25 trials

• Evaluating Liraglutide in Alzheimer's DiseaseNCT01843075 · Unknown · Phase 2 · 204 participants · Primary completion 2019-12
• Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance ImagingNCT03498001 · Completed · NA · 42 participants · Primary completion 2023-06-06 · BMI 30 or higher

  non-weight indication: cardiovascular

• Diabetes Remote Intervention to improVe Use of Evidence-based MedicationsNCT06046560 · Completed · Results posted · Phase 4 · 200 participants · Primary completion 2023-07-25

  non-weight indication: cardiovascular

• Semaglutide Use in Elderly Obese PatientsNCT05302596 · Completed · Results posted · Phase 2 · 16 participants · Primary completion 2023-10-23 · BMI 30 or higher

  non-weight indication: lean_mass, aging

• Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes MellitusNCT03948347 · Unknown · NA · 1708 participants · Primary completion 2023-12

  non-weight indication: cerebrovascular

• Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 DiabetesNCT05597202 · Unknown · Phase 4 · 22 participants · Primary completion 2024-03

  non-weight indication: inflammation, cardiovascular

• Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older AdultsNCT05786521 · Completed · Results posted · Phase 4 · 20 participants · Primary completion 2024-05-20 · BMI 27 or higher

  non-weight indication: lean_mass, aging

• A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's DiseaseNCT05891496 · Completed · Results posted · Phase 3 · 23 participants · Primary completion 2024-08-19

  non-weight indication: inflammation, alzheimers, immune

• A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesNCT03914326 · Completed · Results posted · Phase 3 · 9651 participants · Primary completion 2024-08-23

  non-weight indication: cardiovascular, cerebrovascular

• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)NCT04777409 · Completed · Phase 3 · 1840 participants · Primary completion 2025-09-15

  non-weight indication: dementia, alzheimers

• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)NCT04777396 · Completed · Phase 3 · 1840 participants · Primary completion 2025-09-16

  non-weight indication: dementia, alzheimers

• Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac SurgeryNCT06361238 · Recruiting · Phase 3 · 260 participants · Primary completion 2027-03-31

  non-weight indication: cardiovascular, perioperative

• Effects of Tirzepatide on Muscle and Vascular Health in Obese Older AdultsNCT06811324 · Recruiting · Phase 2 · 20 participants · Primary completion 2027-04-01 · BMI 30 or higher

  non-weight indication: cardiovascular, muscle

• GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)NCT05356104 · Recruiting · Phase 2 · 110 participants · Primary completion 2027-05

  population of special interest (non-obese / healthy / non-diabetic)

• REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · Active not recruiting · Phase 3 · 7101 participants · Primary completion 2027-09-01

  non-weight indication: cardiovascular, cerebrovascular

• Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With SemaglutideNCT06497595 · Recruiting · NA · 60 participants · Primary completion 2027-09-30 · BMI 27 or higher

  non-weight indication: muscle, nutrition

• Tirzepatide to Slow Biological AgingNCT07220473 · Recruiting · Phase 2 · 90 participants · Primary completion 2027-11 · BMI 27 or higher

  non-weight indication: aging

• COMMETS- Combination MCI Metabolic SyndromeNCT06072963 · Recruiting · Phase 2 · 80 participants · Primary completion 2027-12-01

  non-weight indication: cognition, alzheimers

• Oral Semaglutide in Patients With Alzheimer's DiseaseNCT07200622 · Not yet recruiting · Phase 2 · 60 participants · Primary completion 2027-12-31

  non-weight indication: alzheimers

• A Study of Cardiovascular Events iN Diabetes PlusNCT05441267 · Active not recruiting · Phase 4 · 21296 participants · Primary completion 2028-08-17

  non-weight indication: cardiovascular

• Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 DiabetesNCT07485062 · Not yet recruiting · Phase 4 · 164 participants · Primary completion 2029-05-01

  non-weight indication: cognition, aging

• Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseNCT07651319 · Recruiting · Phase 1, Phase 2 · 30 participants · Primary completion 2029-06

  non-weight indication: inflammation, dementia, alzheimers

• Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)NCT07083154 · Recruiting · Phase 3 · 420 participants · Primary completion 2029-08-01 · BMI 20 or higher

  non-weight indication: cognition, dementia, alzheimers

• HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting SemaglutideNCT07760948 · Not yet recruiting · Phase 2 · 90 participants · Primary completion 2029-11-30

  non-weight indication: muscle, lean_mass, nutrition

• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390 · Recruiting · Phase 3 · 7140 participants · Primary completion 2031-08

  non-weight indication: cardiovascular, kidney